Skip to main content
Premium Trial:

Request an Annual Quote

Matthias Mann Will Go to Munich; Steve Martin left ABI; Three VP s Leave Compugen; Perlegen, Thermo, BioTrove, CeMines Hire New CFO s, and Others

Matthias Mann will move to Munichto become a director at the Max Planck Institute for Biochemistry, effective May 1, 2005. He is currently the director of the Center for Experimental Bioinformatics at the University of Southern Denmark in Odense.


Steve Martin has left his post as director of Applied Biosystems' Discovery Proteomics Small Molecule research center in Framingham, Mass., "to pursue an opportunity with a small startup," the company said today. He is replaced by Peter Juhasz, who joined ABI in 1994.


Kinneret Savitsky, Dorit Bitter, and Michal Preminger will leave Compugen, the Tel Aviv-based company confirmed last week. Savitsky, who is vice president for biology R&D, and Bitter, who is vice president for computational life sciences R&D, will stay with the company for several months as Compugen seeks replacements, according to a company spokeswoman. Preminger is vice president for protein therapeutics, working out of Jamesburg, NJ.


Williams Sims has become Perlegen's new CFO, the Mountain View, Calif.-based company said on Monday. He replaces Matthew Fust, who has joined Jazz Pharmaceuticals as CFO. Sims comes to Perlegen from Clontech Laboratories, where he was CFO until its acquisition by Becton Dickinson, when he became vice president of finance and business operations. He holds an MBA from the Stanford University Graduate School of Business and a bachelor of science in business from Oregon State University.


Perlegen also said yesterday that Russell Singleton has become its vice president for engineering and informatics. Previously, he was president of his own company, developing business and marketing strategies for early-stage biotechnology firms and semiconductor equipment companies. He also held several positions at KLA-Tencor. Prior to that, he led instrumentation and software development programs at Molecular Dynamics. Singleton holds a PhD and a master's degree from the Universityof Illinoisand a bachelor's degree from the Pratt Institute.


David Busam has become CFO as well as vice president of finance and administration at CeMines, the Evergreen, Colo.-based company said last week. He joins CeMines from Denver-based Qwest Communications International, where he was senior director of corporate finance. Busam holds an MBA and a bachelor of science degree in finance from AuburnUniversity.


Alan Barber has become CFO at BioTrove, the Woburn, Mass.-based company said last week. He joins BioTrove from Omnisonics Medical Technologies, where he was CFO. Barber holds a BS degree in accounting from Florida State University.


Peter Wilver has been promoted to CFO at Thermo Electron, effective October 1, the Waltham, Mass.-based company said last week. He succeeds Theo Melas-Kyriazi, who will leave Thermo at the end of September "to pursue entrepreneurial opportunities." Wilver is currently Thermo's vice president of financial operations, he post he has held since 2000. Prior to that, he held finance positions at Honeywell International.


David Ludvigson has been promoted to president and COO of Nanogen, the San Diego-based company said last week. He replaces Bruce Huebner, who resigned "to pursue other interests," and will stay with the company for a transition period of several months. Ludvigson is currently Nanogen's executive vice president and CFO. Ludvigson holds an MS and a BS degree from the Universityof Illinoisin Champaign-Urbana.


Philip Huxley has become senior director of drug discovery at Galapagos Genomics, the Mechelen, Belgium-based company said on Monday. He joins the company from Avidex in Abindgon, UK, where he was head of drug discovery. Huxley obtained a PhD in theoretical chemistry from the Universityof Sussexin Brighton, UK.


Karen Vaccaro will retire as vice president for research and development of Matritech on June 25, the Newton, Mass.-based company said last week. She will continue to advise the company in the future. While Matritech is searching for a successor, Gary Fagan, senior director for product development, will become acting CSO.


Brian Taylor has become president of Growing Company Solutions, a North Potomac, MD-based consulting firm. He was previously director of global strategic marketing for Qiagen. Taylorholds a PhD in biochemistry from the Universityof Washingtonand a BS in biochemistry from the Universityof New Hampshire.


Kevin Bankshas become vice president for business development at Geospiza, the Seattle-based bioinformatics company said today. Prior to joining Geospiza, he worked for a number of informatics companies, including ImageX.com and Microsoft. Banks holds a doctorate in biophysical chemistry.

Christopher Steffen has joined the board of directors of Accelrys, the company said last week. He was vice-chairman and director of Citicorp until he retired in 1996. Steffen is a graduate of the Universityof Michiganand WayneStateUniversity.


Bruce Stillman and Thomas Kelly have jointly received the annual Alfred P. Sloan, Jr. Prize, General Motors said today. They share the $250,000 award, one of three prizes given annually by the General Motors Cancer Research Foundation, for their contributions to the understanding of DNA replications in eukaryotes. Stillman is the president and CEO of Cold Spring Harbor Laboratory in New York. He holds a bachelor's degree from the Universityof Sydneyand a doctorate from Australian National University. Kelly is the director of the Sloan-Kettering Institute in New York City. He received a bachelor's degree, an MD and a PhD from Johns Hopkins University.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.